TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced two significant developments: the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. These moves are designed to accelerate the company's RNA-based therapeutic pipeline, particularly its lead candidate, TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.
Dr. Moore, a renowned expert in molecular imaging and nanomedicine, will provide strategic guidance on research and development efforts. Her appointment is expected to bolster TransCode's scientific leadership as the company advances its immuno-oncology platform. The sponsored research agreement with Michigan State University will support the development of TTX-MC138, including evaluation in combination with other therapies, potentially expanding its therapeutic utility against advanced cancers.
TransCode is a clinical-stage company pioneering RNA-based therapies for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
These announcements come at a critical time for TransCode, as the company seeks to advance its pipeline and address unmet needs in oncology. The collaboration with Michigan State University provides additional research capabilities and resources, while Dr. Moore's expertise is expected to enhance the company's strategic direction.
For more information, the full press release is available here. Additional updates on TransCode Therapeutics can be found in the company's newsroom here.
